Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

NEXT STORY
Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Fastest Single-Cell Spatial Biology System
PREV STORY
BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

iCAD Announces AERB Approval of Xoft System in India

First installation of versatile, multi-platform Xoft System in India demonstrates strong, continued momentum in ...

author_avatar
NASDAQ Market News

National Lipid Association Statement Paper Provides Clinicians with Updated Guidance for Enhanced Value of PCSK9 Use in Select Patient Populations

author_avatar
NASDAQ Market News

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

author_avatar
NASDAQ Market News